Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07511127, who can take part
Where in China
- Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaContact: Luxiang WangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT07511127
- Record updated
- 6 April 2026
- Original description
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.Read full original descriptionShow less
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Patients With Refractory Cytomegalovirus Infection Following Allo-HSCT: a Prospective, Multicenter, Randomized, Controlled Clinical Trial
To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.
Inclusion: First allogeneic hematopoietic stem cell transplantation; Age ≥ 18 years; Confirmed refractory CMV infection; Refractory CMV infection is defined as fulfillment of any one of the following criteria:; Persistent or increasing CMV viremia despite ≥2 weeks of appropriate antiviral therapy-specifically, CMV DNA levels remain unchanged (i.e., change ≤ log₁₀) or increase (i.e., change > log₁₀)-concomitant with lack of clinical improvement or ongoing disease progression; Drug-resistant CMV infection-defined as detection of specific CMV gene mutations associated with reduced susceptibility to one or more anti-CMV agents, in patients who otherwise meet the criteria for refractory CMV infection; Intolerance to anti-CMV therapy-defined as inability to continue antiviral treatment due to severe adverse effects, such as clinically significant bone marrow suppression or renal impairment; Provision of written informed consent and willingness to participate in this clinical study.
Exclusion: Known allergic constitution, particularly hypersensitivity to any component of maribavir; Confirmed HIV infection; Severe impairment of major organ function, including but not limited to respiratory failure, cardiac failure, decompensated hepatic insufficiency, or renal insufficiency; Central nervous system CMV infection; History of substance use disorder or chronic alcoholism that may compromise the validity or interpretation of trial outcomes; Presence of a psychiatric disorder or cognitive impairment precluding the provision of informed consent; Any other condition deemed by the investigator to render the participant unsuitable for enrollment in this clinical trial; Active hepatitis B infection, defined as HBV DNA level ≥ 1 × 10³ IU/mL.